Author of

• 30601

  +

  P2.01 - Advanced NSCLC (ID 159)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30679

    +

    P2.01-70 - Therapy with Osimertinib in Patients with T790M Mutation: Experience of a Portuguese Oncology Center (ID 1461)

    10:15 - 18:15  |  Author(s): Iolanda Vieira
    • Abstract
    • Slides

    Background
    

    Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), was initially approved to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with T790M acquired resistance and recently for first-line treatment in those with EGFR activating mutations.

    The aim of the authors was to evaluate the efficacy of osimertinib in a sample of patients followed at a portuguese cancer center who progressed during prior therapy with EGFR-TKI.

    Method
    

    We treated 26 patients with metastatic NSCLC with osimertinib between January 2017 and June 2018. Data was collected from clinical files. Statistical analysis was performed using SPSS software.

    Result
    

    18 women and 8 men with a median age of 68 (range, 41-81) were included. Median time of follow-up was 13.5 months. The majority (23) were non-smokers and 84.6% had ECOG-PS ≤1. Brain metastasis (BM) was present and stable in 6 patients at the start of therapy. The T790M mutation was diagnosed by liquid biopsy in 61.5%. The disease control rate was 88.5%. Median progression free survival (PFS) was 15 months and was significantly lower in the subgroup with BM (6 months vs. not reached, p = 0.033). The most frequent adverse events were fatigue (46.2%) and thrombocytopenia (38.5%) and one patient had to discontinue treatment for pancytopenia grade ≥3.

    Conclusion
    

    This study revealed similar results to those observed in clinial trials, although with higher PFS. Despite the small sample and limited follow-up time, osimertinib has been shown to be safe and effective in our clinical practice.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.